Tirzepatide
Prescription medication — not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only — it is not a recommendation to obtain or use it without a doctor.
At a glance
- Best for
- Adults with type 2 diabetes and/or obesity (Zepbound also for moderate-to-severe OSA with obesity) under a prescriber
- Typical dose
- Titrated to a maintenance dose of 5, 10, or 15 mg subcutaneously once weekly
- Time to effect
- Glucose lowering within weeks; substantial weight loss over months (peak around 72 weeks)
- Main caution
- Boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma); risk of pancreatitis
What is it
Tirzepatide is a once-weekly dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, given by subcutaneous injection. Acting on both incretin pathways, it improves insulin secretion, suppresses glucagon, slows gastric emptying, and strongly reduces appetite. It is FDA-approved for type 2 diabetes (Mounjaro) and for chronic weight management, including in adults with obstructive sleep apnea and obesity (Zepbound).
Is it worth it for you?
Worth considering if…
- You have type 2 diabetes needing strong glycemic control, prescribed and titrated by a clinician
- You have obesity (BMI >=30) or overweight (BMI >=27) with a weight-related comorbidity, using it with diet and activity
- You have obesity with moderate-to-severe obstructive sleep apnea where weight reduction is a goal
Probably skip if…
- You have a personal or family history of medullary thyroid carcinoma or MEN 2
- You have a history of pancreatitis or cannot tolerate dose titration for GI effects
- You are pregnant or seeking rapid cosmetic weight loss without medical oversight
Evidence at a glance
| Goal | Evidence | Effect | Best fit | Time |
|---|---|---|---|---|
| type 2 diabetes glycemic control | Strong Evidence | HbA1c reduction of roughly 1.8-2.4% versus placebo, superior to comparator GLP-1 and insulins | Adults with type 2 diabetes inadequately controlled on diet or other agents | Weeks |
| chronic weight management in obesity | Strong Evidence | Up to ~21% mean body-weight reduction at the 15 mg dose versus ~3% with placebo at 72 weeks (SURMOUNT-1) | Adults with obesity or overweight with a weight-related condition, without diabetes | Months (continues to ~72 weeks) |
| obstructive sleep apnea with obesity | Good Evidence | Clinically meaningful reduction in apnea-hypopnea index (AHI) versus placebo at 52 weeks (SURMOUNT-OSA) | Adults with obesity and moderate-to-severe obstructive sleep apnea | Months |
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
type 2 diabetes glycemic control
Biomarker supportThe phase-3 SURPASS program randomized adults with type 2 diabetes and showed tirzepatide lowered HbA1c by approximately 1.8-2.4% with substantial weight loss, outperforming semaglutide 1 mg and basal insulins (degludec, glargine) on glycemic and weight endpoints. A large share of participants reached HbA1c below 5.7% (the non-diabetic range). These trials supported approval for type 2 diabetes as Mounjaro.
Bottom line: Tirzepatide delivers among the largest HbA1c reductions of any incretin therapy in type 2 diabetes.
chronic weight management in obesity
Disease adjunctIn the phase-3 SURMOUNT-1 trial, adults without diabetes who received tirzepatide lost about 15%, 19%, and 21% of body weight at the 5, 10, and 15 mg doses versus roughly 3% with placebo over 72 weeks, with many achieving 20% or more loss. SURMOUNT-2 confirmed substantial (somewhat smaller) loss in type 2 diabetes. Weight is largely regained after discontinuation, consistent with chronic-disease management.
Bottom line: Tirzepatide produces the largest mean weight loss yet seen with an injectable incretin drug, sustained while treatment continues.
obstructive sleep apnea with obesity
Disease adjunctThe SURMOUNT-OSA phase-3 trials randomized adults with obesity and moderate-to-severe obstructive sleep apnea (with and without CPAP) and showed tirzepatide markedly reduced the apnea-hypopnea index versus placebo over 52 weeks, alongside weight loss and improvements in related cardiometabolic measures. This supported the obstructive-sleep-apnea-with-obesity indication for Zepbound. It complements, and does not necessarily replace, airway-directed therapy as judged by the clinician.
Bottom line: In obesity with obstructive sleep apnea, tirzepatide meaningfully lowers the AHI, an FDA-approved use.
How to take it
- Typical dose
- Prescriber-titrated: started at 2.5 mg weekly (non-therapeutic starting dose) and increased at >=4-week intervals to a maintenance dose of 5, 10, or 15 mg weekly
- Timing
- Once weekly on the same day, any time of day, with or without meals
- With food
- Independent of food; subcutaneous injection in abdomen, thigh, or upper arm with site rotation
- How long to try
- Chronic therapy; weight is largely regained after stopping, so the prescriber plans long-term use and reassessment
What to track
- HbA1c and fasting glucose (in diabetes)
- Body weight and waist circumference
- Signs of pancreatitis (severe persistent abdominal pain)
- Renal function during GI illness/dehydration
- Gallbladder symptoms; OSA severity (AHI) when treated for sleep apnea
Safety
Common side effects
Nausea, vomiting, diarrhea, constipation (dose-related, usually transient), Abdominal pain and dyspepsia, Decreased appetite, Injection-site reactions, Fatigue
Serious risks
- Boxed warning: thyroid C-cell tumors, including medullary thyroid carcinoma, in rodents (human relevance unknown)
- Acute pancreatitis
- Gallbladder disease (cholelithiasis, cholecystitis)
- Acute kidney injury from dehydration with severe GI symptoms
- Severe hypoglycemia when combined with insulin or sulfonylureas
- Diabetic retinopathy complications in susceptible patients
- Possible reduced efficacy of oral hormonal contraceptives around dose initiation/escalation
Who should avoid it
- People with a personal or family history of medullary thyroid carcinoma
- People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- People with prior serious hypersensitivity to tirzepatide
- People with a history of pancreatitis (use with caution)
- Pregnant individuals
Pregnancy & breastfeeding
Not recommended in pregnancy; discontinue when pregnancy is recognized, as weight loss provides no benefit and safety is not established.
Interactions
Additive glucose lowering raises hypoglycemia risk; doses of these often need reduction
Tirzepatide can reduce contraceptive absorption around initiation and dose escalation; a backup or non-oral method is advised for 4 weeks after starting and after each dose increase
Delayed gastric emptying can alter the rate/extent of absorption of co-administered oral drugs
Changed gastric emptying may affect absorption; monitor INR or drug levels
Choosing a product
Look for
- Only obtain via a licensed prescriber and pharmacy as FDA-approved Mounjaro or Zepbound
- Supplied as a single-dose prefilled pen or vial with verified dose
- Dispensed with titration schedule and counseling on GI effects and contraceptive precautions
Be skeptical of
- Compounded or grey-market 'tirzepatide' from med-spa or research sources with unverified purity or salt form
- Research-only powders sold to be reconstituted for injection
- Any source marketing it for rapid weight loss without medical evaluation or titration
References by claim
type 2 diabetes glycemic control
chronic weight management in obesity
Track Tirzepatide with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.